3 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Withdrawn 3 |
Follow Muscle Hypertonia: new trials by email Literature Review of Muscle Hypertonia trials Research Report on Muscle Hypertonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Effects of Baclofen on Presynaptic Inhibition in Humans Baclofen - Spasticity, Muscle, Spinal Cord Injuries | Phase 2 | Withdrawn | University of Alberta | 2020-01-10 | 2024-09-19 | |
| Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis BGG492, Placebo - Muscle Spasticity Due to Multiple Sclerosis | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-10-01 | 2017-04-20 |
Muscle Spasticity (3) · Marijuana Abuse (1) · Multiple Sclerosis (1) · Neuromyelitis Optica (1) · Spinal Cord Injuries (1)
Muscular Diseases (3) · Musculoskeletal Diseases (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1)
Baclofen (1) · nabiximols (1) · selurampanel (1)
Michael, Levy M.D.,Ph.D. (1) · Novartis Pharmaceuticals (1) · University of Alberta (1)
Canada (1) · United States (1)
Anastasia Vishnevetsky, MD, PhD (1) · Michael Levy, MD, PhD (1) · Monica Gorassini, PhD (1)